Earnings Call Summary | ICAD Inc(ICAD.US) Q4 2023 Earnings Conference
Earnings Call Summary | ICAD Inc(ICAD.US) Q4 2023 Earnings Conference
The following is a summary of the ICAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript:
以下是ICAD公司（ICAD）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
iCAD reported annual revenue of $17.3 million in 2023, a decrease of 13% compared to 2022, due to a shift in revenue model and a reduction in salesforce.
Q4 2023 revenue was $4.7 million, a 2% increase from Q4 2022; gross profit margin for Q4 2023 was 91%, an increase from 84% in Q4 2022.
Total operating expenses decreased by 22% YoY, with non-GAAP adjusted EBITDA loss reducing to $0.4 million in Q4 2023.
iCAD improved its cash balance by 61% YoY due to cost savings initiatives and converting to subscription-based model.
The company ensured they have sufficient resources to fund current operations with no need to raise additional funding.
iCad報告稱，由於收入模式的轉變和銷售隊伍的減少，2023年的年收入爲1730萬美元，與2022年相比下降了13％。
2023年第四季度收入爲470萬美元，較2022年第四季度增長2％；2023年第四季度的毛利率爲91％，高於2022年第四季度的84％。
總運營支出同比下降22％，非公認會計准則調整後的息稅折舊攤銷前利潤虧損在2023年第四季度減少至40萬美元。
由於成本節約計劃和向訂閱模式的轉換，iCad的現金餘額同比增長了61％。
該公司確保他們有足夠的資源爲當前的業務提供資金，無需籌集額外資金。
Business Progress:
業務進展：
iCAD is transitioning to a subscription-based model, offsetting a decline in product revenue by a small increase in service revenue.
The company reported 36% growth in annual recurring revenue following the introduction of the new model.
The leadership team expanded with new executive appointments to drive business growth.
iCAD's operational updates included forming partnerships with industry leaders, submitting solutions for FDA review, and planning to introduce ProFound AIs to new markets.
ICAD closed 80 perpetual and 9 subscription orders in Q4 2023, while also aiming to deepen business with existing accounts, expand sales channels, and increase its geographic reach.
ProFound 4.0 and Breast arterial calcification solution are under FDA review and are expected to be cleared for market later this year.
Demand for iCAD's technology remains strong, and the company is focusing on long-term strategies that will contribute to shareholder value.
iCad正在向基於訂閱的模式過渡，服務收入的小幅增長抵消了產品收入的下降。
該公司報告稱，在推出新模式後，年度經常性收入增長了36％。
領導團隊擴大了規模，任命了新的高管，以推動業務增長。
iCad的運營更新包括與行業領導者建立合作伙伴關係，提交解決方案供美國食品藥品管理局審查，以及計劃向新市場引入ProFound AI。
ICAD在2023年第四季度完成了80份永久訂閱訂單和9份訂閱訂單，同時還旨在深化與現有客戶的業務，擴大銷售渠道並擴大其地域覆蓋範圍。
InForend 4.0和乳腺動脈鈣化解決方案正在接受美國食品藥品管理局的審查，預計將於今年晚些時候批准上市。
對iCad技術的需求仍然強勁，該公司將重點放在有助於提高股東價值的長期戰略上。
More details: iCAD Inc IR
更多詳情： iCad Inc IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。